Back to results
US 12,146,170 B2Granted
Engineered enzyme
AssigneeInscripta, Inc.
InventorsJuhan Kim, Benjamin Mijts
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a novel catalytically inactive MAD7 nuclease (dMAD7) that retains the ability to bind DNA in a sequence-specific manner. The MAD7 nuclease from which the dMAD7 has been derived was isolated from Eubacterium rectale.
Claims20
A catalytically inactive CRISPR nuclease comprising a variant amino acid sequence of SEQ ID NO:
- 1, and wherein the variant amino acid sequence comprises an alanine residue at amino acid position 877 as compared to SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.